0000930413-17-003670.txt : 20171030 0000930413-17-003670.hdr.sgml : 20171030 20171030211819 ACCESSION NUMBER: 0000930413-17-003670 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171027 FILED AS OF DATE: 20171030 DATE AS OF CHANGE: 20171030 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Brien James Michael CENTRAL INDEX KEY: 0001632111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 171163855 MAIL ADDRESS: STREET 1: C/O ENZO BIOCHEM INC. STREET 2: 527 MADISON AVE. CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 4 1 c89632_4.xml X0306 4 2017-10-27 0 0000316253 ENZO BIOCHEM INC ENZ 0001632111 O'Brien James Michael C/O ENZO BIOCHEM INC. 527 MADISON AVE. NEW YORK NY 10022 0 1 0 0 EVP of Finance Common Stock 2017-10-27 4 M 0 6699 2.75 A 34886 D Common Stock 2017-10-27 4 M 0 7500 3.40 A 42386 D Common Stock 2017-10-27 4 M 0 8667 4.35 A 51053 D Common Stock 2017-10-27 4 S 0 6699 10.28 D 44354 D Common Stock 2017-10-27 4 S 0 7500 10.28 D 36854 D Common Stock 2017-10-27 4 S 0 8667 10.28 D 28187 D Stock Option (to acquire common stock) 2.75 2017-10-27 4 M 0 6699 2.75 D 2015-02-04 2019-02-03 Common Stock 6699 68501 D Stock Option (to acquire common stock) 3.40 2017-10-27 4 M 0 7500 3.40 D 2016-01-22 2020-01-21 Common Stock 7500 61001 D Stock Option (to acquire common stock) 4.35 2017-10-27 4 M 0 8667 4.35 D 2017-03-15 2021-03-15 Common Stock 8667 52334 D The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ James Michael O'Brien 2017-10-30